Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Host Virtual R&D Day on July 22, 2021
Widely Recognized Experts and AGTC Leadership Will Expand on Recent ACHM Phase 1/2 Clinical Trial Data and Discuss XLRP Milestones Webcast Scheduled from 10:00 am - 1:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 08, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation
View HTML
Toggle Summary AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene
- Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing- - Dosing of pediatric patients in ACHM B3 program and ACHM A3 program is expected to be completed in August 2021 - - Conference call to review data today at 8:00am ET - GAINESVILLE, Fla.
View HTML
Toggle Summary AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC to Present at American Optometric Association’s Optometry’s Meeting
-AGTC patient advocacy executive director will highlight the state of gene therapy  trial recruitment for IRDs- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , June 22, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical
View HTML
Toggle Summary AGTC Expands Leadership Team with Appointment of Key Regulatory Leader
AGTC Appoints Regulatory Expert, Janet C. Rae , RAC, as SVP of Global Regulatory and Quality GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021
- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials - - Company on track to provide multiple data readouts for its XLRP
View HTML
Toggle Summary AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates
- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility - - Obtained additional $10 million in debt and maturity extension under an amended loan agreement with Hercules - GAINESVILLE, Fla. and CAMBRIDGE, Mass.
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today
View HTML
Toggle Summary AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT
-Improved process and validated expression assay support clinical phase product release for the Vista Phase 2/3 XLRP clinical trial- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting
View HTML
Toggle Summary AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials- -Best Corrected Visual Acuity (BCVA) data continue to provide supportive evidence of biological response at 12 months- -Data from a subset of Group 4 patients available for
View HTML
Visionary science for life changing cures.